ATS View
한국어

Korea Arlico Pharm KRX:260660KOSDAQ

알리코제약 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days3
DART filings, 7 days3
Articles tracked3since Sep 11

In Q2 2026, Korea Arlico Pharm reported revenue of ₩46.9bn, down 6.8% year on year, and an operating loss of ₩4.6bn. Korea Arlico Pharm (알리코제약) appeared in 3 Korean news articles and 3 DART filings over the past seven days. Coverage peaked on Sep 11 with 3 articles.

Korea Arlico Pharm quarterly results separate, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩46.9bn-6.8%−₩4.6bn−₩694m
Q1 2026₩48.3bn-4.1%−₩1.8bn−₩621m
Q4 2025 derived₩48.3bn-7.7%−₩1.7bn−₩983m
Q3 2025₩102bn+109.9%₩1.7bn−₩21m
Q2 2025₩50.3bn+11.9%₩1.7bn₩533m
Q1 2025₩50.4bn+13.6%₩1.0bn₩399m
Q4 2024 derived₩52.3bn+17.7%−₩642m−₩1.7bn
Q3 2024₩48.8bn+8.3%₩1.3bn₩1.1bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Korea Arlico Pharm top stories 2 weeks, by number of outlets

  1. 1
    알리코제약, 김대훈 대표 선임…이항구 회장과 각자대표 체제
    2 outlets · 2 articlesFirst report Sep 11 12:18 메디파나뉴스
  2. 2
    [HIT 알공] 알리코제약, 이항구·김대훈 각자 대표이사 체제 변경
    1 outlets · 1 articlesFirst report Sep 11 18:03 히트뉴스

Latest Korea Arlico Pharm news Korean headlines